NCT05739279 Sarcopenia and Related Factors in Lipedema
| NCT ID | NCT05739279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dokuz Eylul University |
| Condition | Lipedema |
| Study Type | OBSERVATIONAL |
| Enrollment | 102 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 102 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lipedema is a common disease of subcutaneous adipose tissue. The most common complaint of patients with swelling in the affected extremity is pain. In addition, patients with lipedema may experience conditions that can greatly affect the health and quality of life of the individual, such as loss of muscle strength and exercise capacity, and deterioration in activity levels of daily living. It is still unknown whether the decrease in muscle strength in patients with lipedema is part of this condition or whether decreased activity levels lead to decreased muscle strength. Sarcopenia is an important health problem characterized by age-related loss of muscle mass and muscle function. The relationship between muscle weakness and sarcopenia in patients with lipedema has not been investigated before. Early recognition of possible sarcopenia and functional limitations in these patients may be important to increase the ability of patients to participate in physical activity as part of their conservative management. There is no study in the literature investigating sarcopenia in patients with a diagnosis of lipedema. The aim of this study is to evaluate patients with a diagnosis of lipedema in terms of sarcopenia. In addition, the relationship between sarcopenia and age, body mass index, exercise frequency, lipedema type, and stage will be investigated in patients diagnosed with lipedema.
Eligibility Criteria
Inclusion Criteria: * between the ages of 18-85 * with a diagnosis of lipoedema * who agreed to participate in the study * having a sociocultural level suitable for participation in the study * healthy volunteers in a similar age group for the control group Exclusion Criteria: * with chronic venous insufficiency and/or lymphedema * with Parkinson's disease, previous stroke, cerebellar diseases, multiple sclerosis, major depression, neuromuscular diseases, history of major orthopedic surgery, severe hip/knee osteoarthritis, rheumatological diseases, malignancies, advanced heart/liver/renal failure, visual impairment, and vestibular diseases, and those who use any assistive device to walk * who are illiterate and have cognitive impairment that will prevent them from giving written consent will not be included in the study
Contact & Investigator
Nihan Erdinc Gunduz, M.D.
STUDY DIRECTOR
Dokuz Eylul University
Frequently Asked Questions
Who can join the NCT05739279 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 85 Years, studying Lipedema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05739279 currently recruiting?
Yes, NCT05739279 is actively recruiting participants. Contact the research team at nihanerdinc@gmail.com for enrollment information.
Where is the NCT05739279 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT05739279 clinical trial?
NCT05739279 is sponsored by Dokuz Eylul University. The principal investigator is Nihan Erdinc Gunduz, M.D. at Dokuz Eylul University. The trial plans to enroll 102 participants.